In this newly updated and revised second edition, Leonard Wartofsky, MD, past president of the American Thyroid Association, and a panel of world-class clinicians critically review all aspects of thyroid cancer from pathogenesis to prognosis, including management and treatment. Organized for rapid access by busy physicians, the book covers both differentiated tumors (papillary carcinoma and follicular carcinoma) and undifferentiated cancers (anaplastic carcinoma, lymphoma, and medullary carcinoma), as well as miscellaneous and unusual cancers of the thyroid. For each tumor type the authors succinctly discuss the key aspects of their clinical presentation, cytology, diagnosis, nuclear isotope scanning evaluation, cellular and biochemical markers, imaging by MRI or CT, monitoring, surgery, pathology, post-operative care, and prognosis. Authoritative and evidenced-based, this second edition of Thyroid Cancer: A Comprehensive Guide to Clinical Management provides in one place everything that physicians treating thyroid cancer patients need to know.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
EUR 48,99 expédition depuis Allemagne vers Etats-Unis
Destinations, frais et délaisVendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Includes supplementary material: sn.pub/extrasare new to this edition. The authors provide not only the The second edition of Thyroid Cancer: A Comp- most current review of their respective areas, but also their hensive Guide to Clinical Manageme. N° de réf. du vendeur 4256905
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -are new to this edition. The authors provide not only the The second edition of Thyroid Cancer: A Comp- most current review of their respective areas, but also their hensive Guide to Clinical Management marks the pub- own recommendations and approach. The reader is fo- cation of a markedly updated and expanded volume that warned that in many cases these approaches, albeit rooted covers all aspects of the etiology, pathogenesis, diag- sis, initial treatment, and long-term management of all in available data, may be empiric rather than based varieties of thyroid cancer. Like the first edition, it will upon clear-cut results of well-controlled clinical t- als. Nevertheless, controversial issues are examined serve as a valuable reference source for pathologists, and evidence-based recommendations are presented endocrine surgeons, endocrinologists, nuclear medicine when available. physicians, and oncologists. However, the biggest There are updated chapters on our current state change is that the second edition is significantly enlarged and expanded to encompass important and extensive of knowledge of the molecular changes in thyroid treatments of more topics related to nuclear medicine. cancer, molecular markers, and how targeted the- pies are being developed. New therapeutic trials of Nuclear medicine physicians and procedures play a key redifferentiation agents to restore the sodium iodide role in the management of thyroid cancer patients and in symporter when lacking and more traditional che- retrospect, a comprehensive discussion of topics related therapies are discussed, with referral sources listed for to that field was somewhat lacking in the first edition. 748 pp. Englisch. N° de réf. du vendeur 9781617375835
Quantité disponible : 2 disponible(s)
Vendeur : Ria Christie Collections, Uxbridge, Royaume-Uni
Etat : New. In. N° de réf. du vendeur ria9781617375835_new
Quantité disponible : Plus de 20 disponibles
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - are new to this edition. The authors provide not only the The second edition of Thyroid Cancer: A Comp- most current review of their respective areas, but also their hensive Guide to Clinical Management marks the pub- own recommendations and approach. The reader is fo- cation of a markedly updated and expanded volume that warned that in many cases these approaches, albeit rooted covers all aspects of the etiology, pathogenesis, diag- sis, initial treatment, and long-term management of all in available data, may be empiric rather than based varieties of thyroid cancer. Like the first edition, it will upon clear-cut results of well-controlled clinical t- als. Nevertheless, controversial issues are examined serve as a valuable reference source for pathologists, and evidence-based recommendations are presented endocrine surgeons, endocrinologists, nuclear medicine when available. physicians, and oncologists. However, the biggest There are updated chapters on our current state change is that the second edition is significantly enlarged and expanded to encompass important and extensive of knowledge of the molecular changes in thyroid treatments of more topics related to nuclear medicine. cancer, molecular markers, and how targeted the- pies are being developed. New therapeutic trials of Nuclear medicine physicians and procedures play a key redifferentiation agents to restore the sodium iodide role in the management of thyroid cancer patients and in symporter when lacking and more traditional che- retrospect, a comprehensive discussion of topics related therapies are discussed, with referral sources listed for to that field was somewhat lacking in the first edition. N° de réf. du vendeur 9781617375835
Quantité disponible : 1 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 2nd edition. 708 pages. 10.75x8.25x1.50 inches. In Stock. N° de réf. du vendeur x-1617375837
Quantité disponible : 2 disponible(s)